中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2014年
10期
1477-1478
,共2页
吡柔比星%膀胱灌注%非肌层浸润性膀胱癌%复发
吡柔比星%膀胱灌註%非肌層浸潤性膀胱癌%複髮
필유비성%방광관주%비기층침윤성방광암%복발
Theprubicin%Intravesical perfusion%Normuscle invasive bladder cancer%Recurrence
目的：观察吡柔比星膀胱灌注防治初发非肌层浸润性膀胱癌术后复发的临床效果和毒副反应。方法将58例非肌层浸润性膀胱癌手术患者按数字表法随机分为观察组和对照组，每组各29例。两组均采用经尿道膀胱肿瘤电切术治疗，术后观察组采用吡柔比星膀胱灌注治疗，对照组采用丝裂霉素C（ MMC）膀胱灌注治疗，随访1年评价两组复发率，观察毒副反应。结果观察组随访期内总复发率为10．3％，对照组总复发率为20．7％，两组差异有统计学意义（χ2＝13．880，P＜0．05）；观察组毒性反应发生率为24．1％，低于对照组的27．5％，两组差异无统计学意义（χ2＝0．090，P＞0．05）；Ⅱ～Ⅲ级不良反应发生率观察组为6．8％，对照组为17．2％，两组差异有统计学意义（χ2＝16．960，P＜0．05）。结论吡柔比星膀胱灌注可以有效地预防非肌层浸润性膀胱癌的术后复发，且毒副作用小，是一种疗效确切、安全可靠的膀胱灌注药物。
目的：觀察吡柔比星膀胱灌註防治初髮非肌層浸潤性膀胱癌術後複髮的臨床效果和毒副反應。方法將58例非肌層浸潤性膀胱癌手術患者按數字錶法隨機分為觀察組和對照組，每組各29例。兩組均採用經尿道膀胱腫瘤電切術治療，術後觀察組採用吡柔比星膀胱灌註治療，對照組採用絲裂黴素C（ MMC）膀胱灌註治療，隨訪1年評價兩組複髮率，觀察毒副反應。結果觀察組隨訪期內總複髮率為10．3％，對照組總複髮率為20．7％，兩組差異有統計學意義（χ2＝13．880，P＜0．05）；觀察組毒性反應髮生率為24．1％，低于對照組的27．5％，兩組差異無統計學意義（χ2＝0．090，P＞0．05）；Ⅱ～Ⅲ級不良反應髮生率觀察組為6．8％，對照組為17．2％，兩組差異有統計學意義（χ2＝16．960，P＜0．05）。結論吡柔比星膀胱灌註可以有效地預防非肌層浸潤性膀胱癌的術後複髮，且毒副作用小，是一種療效確切、安全可靠的膀胱灌註藥物。
목적：관찰필유비성방광관주방치초발비기층침윤성방광암술후복발적림상효과화독부반응。방법장58례비기층침윤성방광암수술환자안수자표법수궤분위관찰조화대조조，매조각29례。량조균채용경뇨도방광종류전절술치료，술후관찰조채용필유비성방광관주치료，대조조채용사렬매소C（ MMC）방광관주치료，수방1년평개량조복발솔，관찰독부반응。결과관찰조수방기내총복발솔위10．3％，대조조총복발솔위20．7％，량조차이유통계학의의（χ2＝13．880，P＜0．05）；관찰조독성반응발생솔위24．1％，저우대조조적27．5％，량조차이무통계학의의（χ2＝0．090，P＞0．05）；Ⅱ～Ⅲ급불량반응발생솔관찰조위6．8％，대조조위17．2％，량조차이유통계학의의（χ2＝16．960，P＜0．05）。결론필유비성방광관주가이유효지예방비기층침윤성방광암적술후복발，차독부작용소，시일충료효학절、안전가고적방광관주약물。
Objective To observe the effect and safety of intravesical perfusion of theprubicin ( THP) on postoperative recurrence of normuscle invasive bladder cancer .Methods According to digital table , a total of 58 cases received bladder cancer surgery were randomly divided into observation group and control group .All patients were treated by TURBt surgery .Patients in observation group were treated by THP intravesical perfusion , while patients in control group were treated by intravesical perfusion of mitomycin ( MMC) .A 1-year follow-up was conduc-ted to evaluate the recurrence rate and the toxicity .Results The recurrence rate of observation group in the follow-up period was 10.3%,while the control group was 20.7%,the difference was significant (χ2 =13.880,P<0.05).The incidence rate of toxicity of the observation group was 24.1%,which was lower than 27.5%of the control group ,but the difference was not significant (χ2 =0.090,P>0.05).The incidence rate of Ⅱ-Ⅲgrade toxicity in the observation group was 6.8%,while the control group was 17.2%,the difference was significant (χ2 =16.960,P <0.05). Conclusion The THP intravesical perfusion can prevent postoperative recurrence of normuscle invasive bladder cancer,with less toxicity.THP is effective,safe and reliable.
